Clinical Spectrum and Outcome of Patients with Graves’ Disease: A Single-Center Experience from a Tertiary Care Institution in the Kashmir Valley, India

Mohammad Hayat Bhat, J. Bhat, S. Masoodi, W. Qureshi, Junaid Rashid Dar, M. Bhat
{"title":"Clinical Spectrum and Outcome of Patients with Graves’ Disease: A Single-Center Experience from a Tertiary Care Institution in the Kashmir Valley, India","authors":"Mohammad Hayat Bhat, J. Bhat, S. Masoodi, W. Qureshi, Junaid Rashid Dar, M. Bhat","doi":"10.25179/TJEM.2020-77446","DOIUrl":null,"url":null,"abstract":"Objective: Graves’ disease (GD) is a common autoimmune disorder with variable outcomes. We aim to study the clinical manifestations and treatment outcome of GD in the post-iodization scenario. Material and Methods: The present study was designed as a cross-sectional study, in which a total of 180 patients with GD (127 males and 53 females) attending our center were reviewed retrospectively. The demographic data, modes of treatment, comorbidities, remission, and recurrence rates were determined for the patients. All patients were initially treated with anti-thyroid drugs (ATDs), with the subsequent management depending on the course of the disease. Results: The mean (±SD) age at diagnosis was 38.30 (10.73) years and the lag period between the onset of symptoms and the diagnosis was 5.12 (2.69) months, with the male patients having a significantly shorter duration of illness compared to females (4.36 vs. 5.44 months; P=0.015). Majority of the patients presented with the typical symptoms and signs associated with hyperthyroidism and/or goiter, although the atypical presentations were not uncommon. ATDs were the most preferred treatment modality employed to achieve clinical and biochemical remission. The mean duration of achieving euthyroidism and the normalization of TSH levels were 3.31±1.51 and 7.45±3.35 months, respectively. On follow-up at three months, 46.1% of the patients were euthyroid, with normalization of the TSH levels in 15.6% of them. Failure to achieve early remission/disease control was significantly higher in males (p=0.003) and smokers (p=0.036). Among the 72 patients who completed medical therapy, 49 patients achieved remission, of whom 20 patients relapsed with a first-year relapse rate of 20.4%. Disease relapse was significantly associated with higher initial 99 mTechnetium (99mTc) uptake (p=0.022) and higher grade of goiter (p=0.026) at presentation. The logistic regression analysis revealed male gender (p=0.048) and orbitopathy (p=0.036) as the independent risk factors predicting relapse of the GD. Conclusion: Graves’ disease manifests with varied clinical manifestations, including the atypical ones, warranting careful clinical assessment to ensure an accurate diagnosis. Gender and orbitopathy are the independent risk factors predicting the relapse of the disease.","PeriodicalId":425605,"journal":{"name":"The Turkish Journal of Endocrinology and Metabolism","volume":"84 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Turkish Journal of Endocrinology and Metabolism","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.25179/TJEM.2020-77446","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Graves’ disease (GD) is a common autoimmune disorder with variable outcomes. We aim to study the clinical manifestations and treatment outcome of GD in the post-iodization scenario. Material and Methods: The present study was designed as a cross-sectional study, in which a total of 180 patients with GD (127 males and 53 females) attending our center were reviewed retrospectively. The demographic data, modes of treatment, comorbidities, remission, and recurrence rates were determined for the patients. All patients were initially treated with anti-thyroid drugs (ATDs), with the subsequent management depending on the course of the disease. Results: The mean (±SD) age at diagnosis was 38.30 (10.73) years and the lag period between the onset of symptoms and the diagnosis was 5.12 (2.69) months, with the male patients having a significantly shorter duration of illness compared to females (4.36 vs. 5.44 months; P=0.015). Majority of the patients presented with the typical symptoms and signs associated with hyperthyroidism and/or goiter, although the atypical presentations were not uncommon. ATDs were the most preferred treatment modality employed to achieve clinical and biochemical remission. The mean duration of achieving euthyroidism and the normalization of TSH levels were 3.31±1.51 and 7.45±3.35 months, respectively. On follow-up at three months, 46.1% of the patients were euthyroid, with normalization of the TSH levels in 15.6% of them. Failure to achieve early remission/disease control was significantly higher in males (p=0.003) and smokers (p=0.036). Among the 72 patients who completed medical therapy, 49 patients achieved remission, of whom 20 patients relapsed with a first-year relapse rate of 20.4%. Disease relapse was significantly associated with higher initial 99 mTechnetium (99mTc) uptake (p=0.022) and higher grade of goiter (p=0.026) at presentation. The logistic regression analysis revealed male gender (p=0.048) and orbitopathy (p=0.036) as the independent risk factors predicting relapse of the GD. Conclusion: Graves’ disease manifests with varied clinical manifestations, including the atypical ones, warranting careful clinical assessment to ensure an accurate diagnosis. Gender and orbitopathy are the independent risk factors predicting the relapse of the disease.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
格雷夫斯病患者的临床谱和预后:来自印度克什米尔山谷三级医疗机构的单中心经验
目的:Graves病(GD)是一种常见的自身免疫性疾病,预后多变。我们的目的是研究碘化后GD的临床表现和治疗结果。材料与方法:本研究设计为横断面研究,回顾性分析本中心共180例GD患者(男性127例,女性53例)。确定患者的人口统计数据、治疗方式、合并症、缓解和复发率。所有患者最初均使用抗甲状腺药物(ATDs)治疗,随后根据病程进行治疗。结果:诊断时的平均(±SD)年龄为38.30(10.73)岁,从症状出现到诊断的滞后时间为5.12(2.69)个月,男性患者病程明显短于女性(4.36 vs. 5.44个月;P = 0.015)。大多数患者表现出与甲状腺功能亢进和/或甲状腺肿相关的典型症状和体征,尽管非典型表现并不罕见。ATDs是实现临床和生化缓解的首选治疗方式。达到甲亢的平均时间为3.31±1.51个月,TSH水平恢复正常的平均时间为7.45±3.35个月。随访3个月,46.1%的患者甲状腺功能正常,15.6%的患者TSH水平恢复正常。在男性(p=0.003)和吸烟者(p=0.036)中,未能实现早期缓解/疾病控制的比例明显更高。在完成药物治疗的72例患者中,49例患者缓解,其中20例复发,第一年复发率为20.4%。疾病复发与首发时较高的99 mtc (99mTc)摄取(p=0.022)和较高程度的甲状腺肿(p=0.026)显著相关。logistic回归分析显示男性(p=0.048)和眼病(p=0.036)是预测GD复发的独立危险因素。结论:Graves病临床表现多样,有不典型的临床表现,应仔细临床评估,以确保准确诊断。性别和眼病是预测疾病复发的独立危险因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Evidence-Based Medicine or Patient-Directed Treatment? Comparison of Screening Strategies for Bone Mineral Density Measurement Overlapping Between Thymus Neuroendocrine Carcinoma as an Ectopic Cushing Syndrome and Exogenous Cushing’s Syndrome: A Case Report Postpartum Metabolic Outcomes and Related Factors in Women with Gestational Diabetes Mellitus History A Case of Plurihormonal Pituitary Giant Macroadenoma
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1